Abstract
Summary
Estrogenic activity of 17α-ethynyl-19-norandrost-4-ene-3β,10β,17β,-triol, a urinary metabolite of norethynodrel, was investigated. The compound exhibited slight estrogenicity when administered subcutaneously. Gavage resulted in increased estrogenicity. Within a limited dose range, injection of the compound together with estrone resulted in synergistic estrogenic activity.
Get full access to this article
View all access options for this article.